Samik Pharm

014950 · KOSDAQ · ₩014950 · 삼익제약

₩7,690▲ ₩670 (9.54%)End-of-day · Oct 28, 2026 · End-of-day prices.
Trade
Alert me

Valuation model · Discounted cash flow (DCF)

We use a 5-year discounted cash flow: the value of the cash the business is expected to produce, in today's money.

Fair value per share

₩4,805

vs the current price (₩7,690)

Enterprise value
₩21B
Equity value
₩48B
WACC
7.4%

Model estimate based on the assumptions shown. Not a price target and not a buy or sell signal. This is not financial advice.

Why the model and the price differ

The model is 38% away from today's price. A gap this size usually means the market expects something the past figures don't show yet, or the model leaves something out. What we can see:

  • To match today's price of ₩7,690, the model needs an operating margin of 7.5% every year (it uses 4.2%).

Treat the model as a starting point: change the assumptions to the story you believe, and compare with the multiples check below.

Bear / Base / Bull

Bear
₩3,159
−58.9%
Base
₩4,805
−37.5%
Bull
₩7,893
+2.6%

Bear: revenue growth 3 points lower every year, EBIT margin 2 points lower, WACC 1 point higher. Bull: the opposite.

Assumptions

Sign in to change the assumptions and see the results update. Sign in

Cycle options

Margin path

Every year uses the cycle-average margin (4.2%).

Revenue growth

  • 3%

    How much sales grow that year, compared with the year before.

    Default: not enough revenue history, so 3%.

  • 3%

    How much sales grow that year, compared with the year before.

    Default: not enough revenue history, so 3%.

  • 3%

    How much sales grow that year, compared with the year before.

    Default: not enough revenue history, so 3%.

  • 3%

    How much sales grow that year, compared with the year before.

    Default: not enough revenue history, so 3%.

  • 3%

    How much sales grow that year, compared with the year before.

    Default: not enough revenue history, so 3%.

Business

  • 4.2%

    Operating profit as a share of revenue.

    Default: through-the-cycle average of the last 12 months and the last 1 annual reports' operating margins.

  • 27.5%

    Share of operating profit paid as corporate tax.

    Default: Korea's top corporate tax rate (25%) plus 10% local income tax.

  • 4.6%

    The non-cash cost of wearing out equipment, added back to cash flow (% of revenue).

    Default: not in the statements, so 80% of capital spending (most spending replaces equipment that wears out).

  • 5.7%

    Money spent on factories, equipment, software and other long-term assets (% of revenue).

    Default: average of the last 1 annual reports (cash flow statements; equipment and intangibles).

  • 32.8%

    Stock and unpaid customer bills, less unpaid supplier bills, as a % of revenue. Each year's extra revenue ties up this much more cash.

    Default: working capital (current assets less cash and deposits, minus current liabilities other than borrowings) as a share of revenue, averaged over the last 1 years.

Discount rate

  • 2%

    How fast cash flows keep growing every year after year 5.

    Default: about Korea's long-run inflation plus real growth.

  • 4.08%

    Yield on Korea's 10-year government bond: the return with almost no risk.

    Default: Korea Treasury Bond 10-year yield on 2026-10-29.

  • 0.61

    How much the share moves when the market moves: 1 means just like the market.

    Default: 52 weeks of weekly returns against KOSPI (official index); raw beta 0.41, adjusted toward 1 and kept between 0.6 and 2.0.

  • 5.5%

    The extra return investors want for owning shares instead of bonds.

    Default: a typical premium for Korean shares.

  • 5.58%

    The interest rate the company would pay to borrow.

    Default: the 10-year yield plus a 1.5% credit spread.

Starting point

Revenue (TTM to H1 2026)
₩62B
Net debt (borrowings and leases − cash and deposits)
−₩27B
+ Stakes and investments
₩5.5M
Associates, long-term financial assets and deposits (book value)
Shares
10,087,588
Share price
₩7,690
Market cap
₩78B

TTM = trailing 12 months: the last four reported quarters added together. "TTM to H1 2026" is the 12 months up to the latest quarterly or half-year report (H1 = to the end of June). Year 1 grows from there.

Past years and projection

Grey columns are reported results from the annual reports (after-tax EBIT at the model's tax rate), so you can check the growth and margin assumptions against the past. Years 1–5 are the model.

FY2025Year 1Year 2Year 3Year 4Year 5
Revenue₩60B₩64B₩66B₩68B₩70B₩72B
Growth—3.0%3.0%3.0%3.0%3.0%
EBIT₩3.3B₩2.7B₩2.8B₩2.9B₩2.9B₩3B
EBIT margin5.5%4.2%4.2%4.2%4.2%4.2%
After-tax EBIT₩2.4B₩2B₩2B₩2.1B₩2.1B₩2.2B
+ Depreciation—₩2.9B₩3B₩3.1B₩3.2B₩3.3B
− Capital spending₩3.4B₩3.7B₩3.8B₩3.9B₩4B₩4.1B
− Working capital—₩613M₩631M₩650M₩669M₩690M
Free cash flow—₩635M₩654M₩673M₩694M₩714M
Discount factor—0.9310.8660.8060.7510.699
Present value—₩591M₩566M₩543M₩521M₩499M

Terminal value ₩26B, worth ₩18B today: 87% of enterprise value. It assumes spending settles at 110% of depreciation once growth slows to the terminal rate.

Sensitivity

Fair value per share as two inputs change; the middle is the current case.

WACC ↓ · Terminal growth →1.0%1.5%2.0%2.5%3.0%
6.4%₩5,199₩5,257₩5,326₩5,410₩5,517
6.9%₩4,964₩4,999₩5,039₩5,086₩5,143
7.4%₩4,766₩4,784₩4,805₩4,827₩4,853
7.9%₩4,597₩4,604₩4,611₩4,617₩4,623
8.4%₩4,451₩4,450₩4,447₩4,443₩4,436

Now (TTM)

Market cap
₩78B
Enterprise value
₩50B
P/E
—
P/B
1.1×
P/S
1.2×
EV/EBITDA
—
Dividend yield
0.5%

Over time (at each year end)

2025
Price₩13,970
Market cap₩141B
P/E—
P/B2.0×
P/S2.3×
EV/EBITDA—
Dividend yield0.3%

Versus similar companies

CompanyP/EP/BP/SEV/EBITDADividend yield
Samik Pharm—1.1×1.2×—0.5%
Samsung Biologics32.0×7.6×14.0×—0.0%
Celltrion27.9×2.5×9.0×—0.0%
Alteogen80.5×29.0×61.2×—0.1%
SK biopharmaceuticals14.7×5.8×6.8×—0.0%
Yuhan24.0×2.4×2.5×31.3×0.8%
HLB—15.7×55.6×—0.0%
Similar companies (median)27.9×6.7×11.5×31.3×0.0%

Calculated from end-of-day prices and filed financial statements. Not a recommendation. This is not financial advice.

Also known as: Samik Pharm / 삼익제약 / 014950 / KRX:014950

Source: KRX statistical information